Renaissance Capital logo

NeOnc Technologies Holdings Scheduled, Nasdaq: NTHI

Phase 2 biotech developing intranasal and oral therapies for brain cancer.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

Our company was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates. NeOnc has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (“POH”) which is administered to brain cancer patients via intranasal delivery. We have completed human testing in a Phase 1 clinical trial and are currently conducting a Phase 2a trial with recurrent malignant glioma (Grade IV, IDH1 mutant and Grade lll Astrocytoma, IDH1 mutant) patients. Our second lead product, NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol, has completed preclinical testing and has received investigational new drug (IND) approval from the United States Food and Drug Administration (FDA), i.e., it has been authorized to proceed to clinical testing in cancer patients.
more less
IPO Data
IPO File Date 12/18/2023
Offer Price
Price Range $11.25 - $13.75
Offer Shares (mm) 6.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $11.25 - $13.75
Offer Shares (mm) 6.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Loop Capital Markets
Maxim Group LLC
more
Company Data
Headquarters Westlake Village, CA, United States
Founded 2008
Employees 8
Website www.neonctech.com

NeOnc Technologies Holdings (NTHI) Performance